The UAB Comprehensive Cancer Center Senior Leadership is comprised of seven individuals supported by the CCSG: Director - Edward E. Partridge, IVI.D. Deputy Director- Boris C. Pasche, M.D., Ph.D. Associate Director for Basic Research - Etty (Tika) Benveniste, Ph.D. Associate Director for Translational Research - Mary-Ann Bjornsti, Ph.D. Associate Director for Clinical Research - Albert F. LoBuglio, M.D. Associate Director for Prevention and Control - Wendy Demark-Wahnefried, Ph.D. Associate Director for Administration - Michael J. Bertram, Ph.D. There have been major changes in Senior Leadership since the last competitive renewal. Following a national search for a new Director, Dr. Edward E. Partridge was named Director in July of 2007. Dr. Partridge has a longstanding history in the UAB Comprehensive Cancer Center (UAB CCC) and has played various leadership roles over the past two decades. His primary areas of expertise include clinical and cancer control research. Other new Senior Leaders include Dr. Boris C. Pasche as Deputy Director, replacing Dr. Kirby Bland, now Senior Advisor to the Director;Dr. Etty Benveniste as Associate Director for Basic Research, replacing Dr. Robert Diasio, now Director of the Mayo Comprehensive Cancer Center;Dr. Albert LoBuglio as Associate Director for Clinical Research, following Dr. Sam Beenken's departure;Dr. Mary-Ann Bjornsti to the newly created position of Associate Director for Translational Research;Dr. Wendy Demark-Wahnefried as Associate Director for Prevention and Control, replacing Dr. Partridge;and Dr. Michael Bertram as Associate Director for Administration.
Because of the investment of the National Cancer Institute in a Comprehensive Cancer Center, the center needs leadership that understands stewardship of public trust. The UAB CCC leadership's mission is to assure that the center fulfills the NCI goals of reducing morbidity and mortality from cancer;discovering the nature of cancer;understanding cancer biology;developing effective prevention, diagnosis, and therapy.; delivering medical advances to patients and their families;educating healthcare professionals and the public; and reaching out to underserved populations.
|Van Arsdale, Anne R; Arend, Rebecca C; Cossio, Maria J et al. (2018) Insulin-like growth factor 2: a poor prognostic biomarker linked to racial disparity in women with uterine carcinosarcoma. Cancer Med 7:616-625|
|Kim, Harrison (2018) Modification of population based arterial input function to incorporate individual variation. Magn Reson Imaging 45:66-71|
|Leath 3rd, Charles A; Monk, Bradley J (2018) Twenty-first century cervical cancer management: A historical perspective of the gynecologic oncology group/NRG oncology over the past twenty years. Gynecol Oncol 150:391-397|
|Park, Misun; Yoon, Young Sup (2018) Cardiac Regeneration with Human Pluripotent Stem Cell-Derived Cardiomyocytes. Korean Circ J 48:974-988|
|Toboni, Michael D; Smith, Haller J; Bae, Sejong et al. (2018) Predictors of Unplanned Reoperation for Ovarian Cancer Patients From the National Surgical Quality Improvement Program Database. Int J Gynecol Cancer 28:1427-1431|
|Dionne-Odom, J Nicholas; Applebaum, Allison J; Ornstein, Katherine A et al. (2018) Participation and interest in support services among family caregivers of older adults with cancer. Psychooncology 27:969-976|
|Demark-Wahnefried, Wendy; Schmitz, Kathryn H; Alfano, Catherine M et al. (2018) Weight management and physical activity throughout the cancer care continuum. CA Cancer J Clin 68:64-89|
|Bandari, Shyam K; Purushothaman, Anurag; Ramani, Vishnu C et al. (2018) Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior. Matrix Biol 65:104-118|
|Gowda, Pramod S; Wildman, Benjamin J; Trotter, Timothy N et al. (2018) Runx2 Suppression by miR-342 and miR-363 Inhibits Multiple Myeloma Progression. Mol Cancer Res 16:1138-1148|
|Dix, Daniel B; McDonald, Andrew M; Gordetsky, Jennifer B et al. (2018) How Would MRI-targeted Prostate Biopsy Alter Radiation Therapy Approaches in Treating Prostate Cancer? Urology 122:139-146|
Showing the most recent 10 out of 747 publications